Bristol-Myers Squibb (Belgium) - Academic Profile

Publications

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Caroline Robert , L. Thomas , Igor Bondarenko +21 more

Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dacarbazine plus placebo, improved overall survival in patients with previously un...

2011 New England Journal of Medicine 4405 citations

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Stephen M. Ansell , Alexander M. Lesokhin , Ivan Borrello +16 more

Preclinical studies suggest that Reed-Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune detection. In classic Hodgkin's lymphoma, alterations in chro...

2014 New England Journal of Medicine 3484 citations

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber , Sandra P. D’Angelo , David R. Minor +25 more

2015 The Lancet Oncology 2617 citations

Affiliated Researchers

Institution Info

Type: company
Country: BE
Publications: 3
Citations: 10,506

External Links

Identifiers

ROR: https://ror.org/03c09ma81

Publications

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Affiliated Researchers

Li Zhu

Su Young Kim

Stephen Francis

Alexandre Lambert

Institution Info

External Links

Identifiers